Multiple Myeloma

A supplemental biologics license application has been submitted to the FDA for the use of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

​Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.

Andrzej Jakubowiak, MD, discusses the impact of a recent cross-study comparison analysis and the continued role of autologous stem cell transplantation in treatment of patients with multiple myeloma.

Maintenance lenalidomide following frontline treatment with high-dose melphalan and autologous stem cell transplant reduced the risk of death by 26% versus placebo or no maintenance in patients with multiple myeloma.

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Antonio Palumbo, MD, discusses the practice-changing findings of the phase III CASTOR trial for relapsed/refractory patients and what questions remain with the 3-drug regimen.

Michele Cavo, MD, provides insight on the results of the randomized phase III European Myeloma Network EMN02/HO95 MM trial for multiple myeloma.

The European Commission has approved carfilzomib in combination with dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.